AUTHORS
Tanaya Shree, MD,PhD, Titas Banerjee, MD2, Craig Okada, MD, PhD3, Pam St. Clair, NP4, Hong Guo5, Fabian Sanchez6, Annie Evans7, Sashi Mendis8, Nicole Goy9, Chaucie Edwards10, Sarah West11, Kayleigh Day12, Deborah Ryan13, Mark Hoyle14, Stephen E. Spurgeon, MD15
AFFILIATIONS
1 Oregon Health & Science University, Portland, Oregon, United States
2 Oregon Health & Science University, Portland, Oregon, United States
3 Oregon Health & Science University, Portland, Oregon, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 Oregon Health & Science University, Portland, Oregon, United States
7 Oregon Health & Science University, Portland, Oregon, United States
8 Oregon Health & Science University, Portland, Oregon, United States
9 Oregon Health & Science University, Portland, Oregon, United States
10 Oregon Health & Science University, Portland, Oregon, United States
11 Oregon Health & Science University, Portland, Oregon, United States
12 Oregon Health & Science University, Portland, Oregon, United States
13 Oregon Health & Science University, Portland, Oregon, United States
14 Oregon Health & Science University, Portland, Oregon, United States
15 Oregon Health & Science University, Portland, Oregon, United States
ABSTRACT
Background: Time-limited frontline treatment regimens for chronic lymphocytic leukemia (CLL) with a goal of achieving undetectable minimal residual disease (uMRD) have proven to be efficacious and often preferred by patients. However, most patients will ultimately relapse requiring additional therapy. As such, new time-limited therapies capable of producing deeper, longer remissions are needed. This study evaluates the combination of the Fc-modified anti-CD19 immunotherapy tafasitamab in combination with acalabrutinib and obinutuzumab in previously untreated CLL. The TAO triplet aims to 1) synergistically target multiple pathways, 2) reduce drug exposure to limit resistance and toxicity, 3) allow for future BTK inhibitor-based retreatment and/or venetoclax treatment. Further, as T cell directed therapies are developed, regimens that have the potential to maintain or improve T-cell fitness warrant further investigation.
Methods: In this open label single-center Phase 1b study, eligible patients were treated with acalabrutinib (100 mg PO BID) for a total of twelve 28-day cycles. Obinutuzumab was administered cycles 1-6 per standard CLL dosing guidelines. Tafasitamab was administered weekly for cycle 2-4 with one additional dose Day 4 of Cycle 2 and then biweekly in cycles 5-7. Co-primary endpoints include safety and efficacy defined as the number of patients achieving uMRD (≤ 10 -4, Clonoseq® Adaptive Biosciences, Seattle, WA), with MRD assessments occurring every 3 months. Secondary objectives include overall response by iwCLL. Exploratory objectives include progression free (PFS) and overall survival (OS), uMRD ≤10 -6, MRD kinetics, patient reported quality of life outcomes (QOLs), association of response to molecular correlates and baseline biologic characteristics, and analysis of peripheral blood immune populations by flow cytometry.
Results: 22 treatment-naive CLL/SLL patients (median age 68; 13 males, 9 females) were enrolled. 14 had Rai stage 0-2 and 8 had stage 3-4 disease. Disease factors included: del17p (n=1), TP53 mutation (n=2), complex karyotype (n=1), unmutated IGHV (n=15), and CLL- IPI score of ≥3 (n=15). 15 patients have completed all treatment; 3 have completed TO and continue acalabrutinib; and 4 continue on the TAO combination. Median time on-study is 14 months (1-32). 18 subjects are evaluable for MRD. To date, uMRD (<10⁻⁴) in peripheral blood has been achieved in 12 of 18 (67%) evaluable patients, including 11 of 12 (92%) who have completed the 12-month regimen. Best response of uMRD (<10-6) has been seen in 5 patients. The overall response rate in evaluable patients is 100%. 9 of 15 (60%) patients achieving uMRD had CLL-IPI ³ 3. At a median follow up of 11 months (range 0-20 months), 8 of 11 patients who achieved uMRD continue to have uMRD (<10⁻⁴). Two patients experienced rapid tumor flare after discontinuing acalabrutinib and continue acalabrutinib beyond the 12-month study period. One DLT has been observed (grade 3 febrile neutropenia during cycle 3). The most common AE was neutropenia; grade 3, n=8; grade 4, n=3. No grade 3 infections were seen. One case of grade 3 thrombocytopenia was also seen. No tafasitimab infusion reactions were observed.
Immunophenotyping was performed on 35 available peripheral blood samples (5 serial peripheral blood samples each from 7 patients). In all patients, peripheral B cells and NK cells decreased significantly with treatment, while T cells and classical monocytes increased. CD69+ activated CD4 T cells were significantly increased at Cycle 4 Day 1 (C4D1) and a similar trend was observed for activated CD8 T cells. Despite increased activation, PD1 positivity on CD4 T cells decreased with treatment, while no consistent change occurred in PD1 on CD8 T cells. Older patients had fewer CD8 T cells and these T cells were less likely to express CD69 after treatment and more likely to upregulate PD-1. Dynamic post-treatment changes in effector and memory T cells were associated with MRD negativity at C4D1. Further correlation with clinical outcomes are ongoing.
Conclusion: The TAO regimen shows high rates of uMRD without any unexpected safety signals. Post-treatment increases in activated T cells suggest potentially enhanced anti-tumor immune activity with treatment. Longer follow-up will provide additional insight into duration of response, changes in T cell fitness, and associations between immunological findings, age, and clinical response.
DISCLOSURES
Stephen E. Spurgeon, MD: Janssen - Research Funding; Genentech - Research Funding; Astra Zeneca - Research Funding; Genmab - Research Funding; Merck - Research Funding; Incyte - Research Funding; Genentech - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)